https://cancer.holy-cross.com/cancer-clinical-trials
Skip to Content
image description
  • image description
  • image description
  • image description

Cancer Clinical Trials

Advanced ER+/AR+ Breast Cancer

G200802

A Phase 2 Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating The Efficacy and Safety Of GTx-024 On Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in Postmenopausal Women.

Androgen Receptor-Positive Triple Negative Breast Cancer

G200901

A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+TNBC).

Breast - Metastatic, BRCA 1 and BRCA 2

Brocade 3 (M12-914)

A Phase 3 randomized placebo-controlled trial of carboplatin and paclitaxel with or without veliparib (ABT-888) in HER2-negative metastatirc or locally advanced unresectable BRCA-associated breast cancer.
www.Brocade3Study.com

Breast Registry

Nipple Sparing

ASBrS Nipple Sparing Mastectomy Registry.

Breast – Early stage

neoMONARCH

A Phase 2 Neoadjuvant Trial Comparing the Biological Effects of 2 Weeks of Abemaciclib (LY2835219) in Combination with Anastrozole to those of Abemaciclib Monotherapy and Anastrozole Monotherapy and Evaluating the Clinical Activity and Safety of a Subsequent 14 Weeks of Therapy with Abemaciclib in Combination with Anastrozole in Postmenopausal Women with Hormone Receptor Positive, HER2 Negative Breast Cancer.

Colorectal Cancer – Treatment experienced

A Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer.

Gastric – Metastatic

RAINFALL (I4T-MC-JVCU)

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Capecitabine and Cisplatin with or without Ramucirumab as First-line Therapy in Patients with Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. 

Genetic Registry

City of Hope Registry

Molecular Genetics Studies of Cancer Patients and Their Relatives

Lung – Early Stage

G029527

A Phase III, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (ANTI−PD-L1 Antibody) Compared with best Supportive Care Following Adjuvant Cisplatin-Based Chemotherapy in PD-L1−Selected Patients with Completely Resected Stage Ib−IIIa Non−Small Cell Lung Cancer.

Lung – Metastatic

GO29437

A Phase III, Open-label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti−PD-L1 Antibody) in Combination with Carboplatin+Paclitaxel or Atezolizumab in Combination with Carboplatin+Nab-Paclitaxel versus Carboplatin+Nab-Paclitaxel in Chemotherapy-naive Patients with Stage IV Squamous Non−small Cell Lung Cancer.

Lung – Metastatic

G029436

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti−Pd-L1 Antibody) in Combination with Carboplatin + Paclitaxel with or without Bevacizumab Compared with Carboplatin + Paclitaxel + Bevacizumab in Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non−Small Cell Lung Cancer.

Melanoma

Keynote-252 / ECHO-301

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combination With Epacadostat or Placebo in Subjects with Unresectable or Metastatic Melanoma.

Multiple Myeloma

MAIA (54767414MMY3008)

A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy.

Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukemia (AML)

Connect® MDS and AML Registry

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry.

Three Women Photo

Cancer risk assessment, screening and prevention programs are vital to educating people about reducing their chances of developing cancer and assessing the need for intervention. Under the direction of our genetic nurse counselor and the Bienes Cancer Center physicians, our Cancer Risk and Prevention Program is for anyone with cancer or a family history of cancer. The vast majority of participants are women who have or have had breast or ovarian cancer, or are at high risk of developing these two cancers. Click to learn more about Genetic Counseling.

Cancer Resources

More Cancer Resources

®2005-2011 WebMD, LLC. All rights reserved.

WebMD does not provide medical advice, diagnosis or treatment.

See additional information.

Directions

image description